Loading...

Rebecca Deboer, MD

Title(s)Clinical Fellow, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford University, Stanford, CABA06/2005Human Biology
    Northwestern University Feinberg School of Medicine, Chicago, ILMD05/2011
    Northwestern University, Evanston, ILMA03/2014Medical Humanities and Bioethics
    University of Chicago, Chicago, IL06/2016Residency in Internal Medicine
    University of Chicago MacLean Center for Clinical Medical Ethics, Chicago, IL05/2016Fellowship in Clinical Medical Ethics

    Collapse Overview 
    Collapse Overview
    Rebecca (Becky) DeBoer, MD, MA is a senior fellow in medical oncology at UCSF and a Fogarty GloCal Fellow currently based in Rwanda and Tanzania. She received her BA in Human Biology from Stanford University and her joint MD and MA in Medical Humanities and Bioethics from Northwestern University, and wrote her master’s thesis on The Ethics of Global Cancer Care and Control. She completed residency in internal medicine at the University of Chicago and fellowship at the MacLean Center for Clinical Medical Ethics. During her medical training, she conducted qualitative research on cancer treatment decision-making and research ethics in Mumbai, India, and pursued clinical oncology rotations in Uganda and Nigeria. She then worked as an oncology clinician at the Butaro Cancer Center of Excellence in Rwanda with Partners In Health, where she was engaged in direct patient care, clinical research, and programmatic initiatives.

    As a Global Cancer Fellow at UCSF, she is currently leading research on radiotherapy prioritization in the setting of limited resources in Rwanda (supported by a grant from the Greenwall Foundation), clinical decision-making about non-curative cancer treatment in Rwanda and Tanzania (supported by the Fogarty International Center and the National Cancer Institute), and cancer treatment guideline implementation in Tanzania (supported by a Celgene Cancer Care Links grant).

    Collapse Research 
    Collapse Research Activities and Funding
    An Ethical Approach to Routine Tragic Choices: Radiotherapy Allocation in Rwanda
    Greenwall Foundation A131753Jul 1, 2018 - Jun 30, 2020
    Role: Principal Investigator
    University of California Global Health Institute Program for Fellows and Scholars
    NIH/FIC D43TW009343Apr 4, 2012 - Jun 30, 2022
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Global Health
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Xu MJ, Su D, Deboer R, Garcia M, Tahir P, Anderson W, Kinderman A, Braunstein S, Sherertz T. Palliative Oncologic Care Curricula for Providers in Resource-Limited and Underserved Communities: a Systematic Review. J Cancer Educ. 2017 Dec 20. PMID: 29264703.
      View in: PubMed
    2. Rubagumya F, Greenberg L, Manirakiza A, DeBoer R, Park PH, Mpunga T, Shulman LN. Increasing global access to cancer care: models of care with non-oncologists as primary providers. Lancet Oncol. 2017 08; 18(8):1000-1002. PMID: 28759361.
      View in: PubMed
    3. Daly B, Hantel A, Wroblewski K, Balachandran JS, Chow S, DeBoer R, Fleming GF, Hahn OM, Kline J, Liu H, Patel BK, Verma A, Witt LJ, Fukui M, Kumar A, Howell MD, Polite BN. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. J Oncol Pract. 2016 10; 12(10):e901-e911. PMID: 27601514.
      View in: PubMed
    4. DeBoer R, Koval G, Mulkey F, Wetzler M, Devine S, Marcucci G, Stone RM, Larson RA, Bloomfield CD, Geyer S, Mullighan CG, Stock W. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016 10; 57(10):2298-306. PMID: 26892479.
      View in: PubMed
    5. Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 2015 Feb 15; 21(4):870-81. PMID: 25492084.
      View in: PubMed
    6. Raizer JJ, Fitzner KA, Jacobs DI, Bennett CL, Liebling DB, Luu TH, Trifilio SM, Grimm SA, Fisher MJ, Haleem MS, Ray PS, McKoy JM, DeBoer R, Tulas KM, Deeb M, McKoy JM. Economics of Malignant Gliomas: A Critical Review. J Oncol Pract. 2015 01; 11(1):e59-65. PMID: 25466707.
      View in: PubMed
    7. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015 Feb 01; 21(3):632-41. PMID: 25056374; PMCID: PMC4305034.
    8. Parvataneni R, Polley MY, Freeman T, Lamborn K, Prados M, Butowski N, Liu R, Clarke J, Page M, Rabbitt J, Fedoroff A, Clow E, Hsieh E, Kivett V, Deboer R, Chang S. Identifying the needs of brain tumor patients and their caregivers. J Neurooncol. 2011 Sep; 104(3):737-44. PMID: 21311950; PMCID: PMC3170122.
    9. DeBoer R, Batjer H, Marymont M, Goldman S, Walker M, Gottardi-Littell N, Raizer J. Response of an adult patient with pineoblastoma to vorinostat and retinoic acid. J Neurooncol. 2009 Nov; 95(2):289-292. PMID: 19506816.
      View in: PubMed
    10. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 2009 Feb 01; 27(4):579-84. PMID: 19075262; PMCID: PMC2645859.